Viking Therapeutics Raises $500M in Upsized Stock and Convertible Note Offering After Weight-Loss Drug Surge

Viking Therapeutics priced concurrent public offerings totaling roughly $500 million on September 24, 2026, capitalizing on a sharp rally tied to positive results from its VK2735 weight-loss drug. The company sold 7,857,143 shares of common stock at $35.00 per share and priced $225 million in aggregate principal amount of 2.00% convertible senior notes due 2032. Both tranches were upsized from their originally announced targets of $200 million each, bringing the combined deal to approximately $500 million.

VKTX shares had surged roughly 36% on Tuesday after the company reported top-line maintenance-study results for VK2735, its lead obesity candidate, which is now in Phase 3 trials. Management moved quickly to capture that premium, announcing the offering on September 23 and pricing it the following morning. The stock fell approximately 14.5% in early trading on September 24, a typical dilution-driven pullback rather than a reversal of sentiment on the drug's prospects.

Proceeds are intended to fund continued clinical development, including the ongoing Phase 3 program for VK2735. Options implied volatility for VKTX declined following the pricing, consistent with the resolution of deal uncertainty.